Research from Duke University School of Medicine reveals that ascites, a common condition in advanced ovarian cancer, may shield cancer cells from ferroptosis, a form of cell death. This finding suggests that the accumulation of fluid in the abdominal cavity not only causes discomfort but also provides a survival advantage to cancer cells, facilitating their spread. The study indicates that bezafibrate, a cholesterol-lowering drug, could disrupt this protective environment, potentially making cancer cells more susceptible to existing treatments.
Dr. Jen-Tsan Chi, a leading researcher on the study, emphasizes that ascites has been traditionally viewed as a symptom rather than a contributor to cancer progression. The research highlights the need to reconsider the role of biological fluids in cancer metastasis, particularly in the peritoneal cavity, where ascites is prevalent. The study’s findings could have broader implications for other metastatic cancers, suggesting that targeting the tumor microenvironment may enhance treatment efficacy.
Use the database as your supply chain compass →
